Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019–2023

Knight, K.J.; Fordham, R.J.; Crabtree, N.J.; Knapp, K.M.

doi:10.1007/s00198-024-07120-6

Osteoporos Int

2024

DOI: 10.1007/s00198-024-07120-6

|View full text |Cite

Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019–2023

K.J. Knight,

R.J. Fordham,

N.J. Crabtree

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Management of bone health in idiopathic inflammatory myopathies: A two‐center audit in the United Kingdom and Hong Kong

Thumbe,

Kumar,

Ajibade

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

BackgroundPatients with inflammatory idiopathic myopathies (IIM) face elevated risks of osteoporosis and fragility fracture.AimTo evaluate current practice relating to bone health in adult patients with IIM in the United Kingdom and Hong Kong (HK).MethodsPatients were identified from IIM patient lists. Demographics, osteoporosis risk factors, DXA scans, and bone protection treatment were recorded. Adherence to regional standards was evaluated for each center. Following this, in the United Kingdom, up‐to‐date DXA scans were performed.ResultsOf 136 patients identified, 51 met selection criteria (UK, n = 20, HK, n = 31). Mean age in the United Kingdom was 59 (IQR 54–66); in Hong Kong, 65 (IQR 52.5–70). Most were female (UK 70%; HK 77%), current or previous steroid treatment was common (UK 90%; HK 100%) and some had experienced fragility fracture (UK 15%; HK 9%). The mean daily dose of prednisolone that patients were prescribed during the study was 12.5 mg (UK) and 14.3 mg (HK). Some patients had had a DXA scan (UK 50%; HK 35%) though several were outdated. Among those with BMD measured (UK, n = 20; HK, n = 11), osteopenia prevalence was 35% (UK) and 36% (HK) while osteoporosis was 5% (UK) and 36% (HK). Notably, 25% (UK) and 64% (HK) exceeded treatment thresholds. Treatments included anti‐osteoporotic agents (UK 55%; HK 15%), Vitamin D/calcium supplements (UK 95%; HK 52%), or no treatment (UK 5%, HK 15%).ConclusionPoor compliance with guidelines exists in both centers, particularly around investigation and monitoring of bone health for IIM patients. Integrated care models and increased resource allocation to bone health are imperative to improve management of this aspect of IIM.

show abstract

Management of bone health in idiopathic inflammatory myopathies: A two‐center audit in the United Kingdom and Hong Kong

Thumbe,

Kumar,

Ajibade

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019–2023

Cited by 1 publication

References 25 publications

Management of bone health in idiopathic inflammatory myopathies: A two‐center audit in the United Kingdom and Hong Kong

Management of bone health in idiopathic inflammatory myopathies: A two‐center audit in the United Kingdom and Hong Kong

Contact Info

Product

Resources

About